Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02310984
Other study ID # UCL 13/0354
Secondary ID 14/LO/0428
Status Completed
Phase N/A
First received September 3, 2014
Last updated March 16, 2017
Start date March 2014
Est. completion date December 2016

Study information

Verified date October 2016
Source University College, London
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This project which is fully funded by the European Union FP7 Program is designed to pull together all the information we obtain from scans and x-rays to design a personalised 3-D digital model of each patient, their anatomy and disease. We can then use this as follows: as (i) an aid to surgical planning to enable objective clinical decision making (ii) a decision support tool to communicate the available treatment options to the patient and facilitate shared decision making and provision of personalised care and (iii) to enable standardised objective evaluation of the aesthetic outcome of the treatment procedures. This study aims to demonstrate the ability of the Virtual Physiological Human concept to empower breast cancer patients and assess the impact on their care and quality of life.


Description:

Breast cancer is the most common cancer to affect women in Europe, having a lifetime risk of 1 in 9. It is an increasingly treatable disease, and 10-year survival now exceeds 80%. The primary treatment for breast cancer is surgery, which may be used in conjunction with adjuvant therapies, such as chemotherapy and radiotherapy. Given the high breast cancer survival rate, many women will live for many years with the potentially disfiguring aesthetic consequences of their surgical and therapeutic treatment. A good aesthetic outcome is an important endpoint for breast cancer treatment and is closely related to psychosocial recovery and quality of life.

When a woman faces a breast cancer diagnosis, and surgery is proposed, several options are available. The decision as to which type of surgery to offer patients is largely subjective and based almost exclusively on the judgment and experience of the clinician. The cosmetic outcome of surgery is a function of many factors including tumour size and location, the volume of the breast, its density, and the dose and distribution of radiotherapy. In breast-conserving surgery, there is evidence that approximately 30% of women receive a suboptimal or poor aesthetic outcome; however there is currently no standardised method of identifying these women.

The PICTURE project aims to address these issues by providing objective tools, tailored to the individual patient, to predict the aesthetic outcome of local treatment. Using a combination of 3D photography and routinely acquired radiological images (i.e. mammography, ultrasound and MRI, when available), together with information about the tumour (size, location, shape etc.) we will develop techniques to biomechanically model the anatomy of the breast and the effect of surgical removal of cancerous tissue. This digital patient representation and associated predictive tools will enable alternative surgical strategies to be explored and the consequences of the available options, with respect to the appearance of the breast, to be visualised. This will aid communication with the patient of the type of breast surgery recommended by the surgeon, and will empower patients to take an active role in a shared decision making process.

The study will develop tools to enable the patient's aesthetic appearance after treatment to be objectively evaluated. Current techniques use subjective methods, such as assessment by an expert panel, or computer analysis of 2-dimensional photography to estimate, for instance, breast asymmetry. By adopting recent developments in low cost 3D photography and depth sensing technology, we will develop a standardised, reproducible analysis tool which will base the aesthetic outcome evaluation on both the 3-dimensional shape of the reconstructed breast and its volume. This will establish standardised quality assurance and evaluation procedures, enabling institutions across Europe to be compared and factors that have a positive or negative impact on surgical outcome identified.

In summary, the demonstrator created by the PICTURE project will integrate models of surgical techniques and treatment schemes, clinical patient data, multi-modal imaging and individualised models of patient anatomy to build a personalised, digital representation of the patient. The aim is for this to be used as an aid to surgical planning, via simulation of the cosmetic effects of breast conserving surgery, as a decision support tool to communicate the available options to the patient and to enable standardised evaluation and a safe outcome of the procedure. The demonstrator aims to empower patients and will have a direct impact on their care and quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 222
Est. completion date December 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Women who have undergone breast conserving surgery for early breast cancer more than one year ago.

- Written informed consent obtained.

Exclusion Criteria:

- Unable to provide written informed consent.

- Younger than 18 years.

- Benign breast disease.

- Women who have had a mastectomy.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands Leiden University Medical Center (LUMC) Leiden
Portugal Champalimaud Cancer Center Lisbon
United Kingdom Royal Free Hospital London

Sponsors (2)

Lead Sponsor Collaborator
University College, London European Union

Countries where clinical trial is conducted

Netherlands,  Portugal,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate the factors that determine aesthetic outcome after treatment for early breast cancer The primary aim of this study is to evaluate the factors that determine aesthetic outcome after treatment for early breast cancer, based on a consensual classification obtained with a consensus panel. The information thus obtained will be integrated into the demonstrator (a personalised digital representation of the patient). Single assessment on one day, beyond one year from date of primary surgery.
Secondary Comparison of the characteristics of this patient group with the group used to make the demonstrator in PICTURE L (composite outcome). Comparison of the characteristics of the primary tumour in this patient group with the group used to make the demonstrator. The characteristics include: primary tumour side, quadrant, size, and hormone receptor status. Single assessment on one day, beyond one year from date of primary surgery.
Secondary Comparison of the characteristics of this patient group with the group used to make the demonstrator in PICTURE L (composite outcome). Comparison of the characteristics of treatment received in this patient group with the group used to make the demonstrator. The characteristics include: details of surgery, chemotherapy, radiotherapy and adjuvant hormonal therapy. Single assessment on one day, beyond one year from date of primary surgery.
Secondary Comparison of the characteristics of this patient group with the group used to make the demonstrator in PICTURE L (composite outcome). Comparison of the characteristics assessed by questionnaire of this patient group with the group used to make the demonstrator. The characteristics include: measures assessed by the questionnaires (EQ-5D-5L, QLQ-C30 & BR23, and BREAST-Q). Single assessment on one day, beyond one year from date of primary surgery.
See also
  Status Clinical Trial Phase
Recruiting NCT04290897 - Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors Phase 2
Active, not recruiting NCT02592083 - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors Phase 2
Active, not recruiting NCT02568839 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer Phase 2/Phase 3
Completed NCT02481128 - Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer N/A
Active, not recruiting NCT03077841 - Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer Phase 2/Phase 3
Recruiting NCT02511301 - Circadian Thermal Sensing to Detect Breast Disease Phase 1/Phase 2
Active, not recruiting NCT02474641 - Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer N/A
Withdrawn NCT04560439 - Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors N/A
Completed NCT02129686 - A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients N/A
Completed NCT02806817 - ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism Early Phase 1
Recruiting NCT02947425 - TARGeted Intraoperative radioTherapy (TARGIT) Registry Database
Active, not recruiting NCT02603679 - Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases Phase 2
Active, not recruiting NCT03025139 - Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) N/A
Completed NCT04081389 - Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Phase 1
Completed NCT02441946 - A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Phase 2
Completed NCT04294225 - Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer Phase 2